In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile

OBJECTIVES: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). The objective was to determine the comparative susceptibility of 82 C. difficile clinical isolates (which included ribotype 027 isolates and isolates with reduced metr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Antimicrob Chemother
Hlavní autoři: Corbett, D., Wise, A., Birchall, S., Warn, P., Baines, S. D., Crowther, G., Freeman, J., Chilton, C. H., Vernon, J., Wilcox, M. H., Vickers, R. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4498293/
https://ncbi.nlm.nih.gov/pubmed/25652750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv006
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky